Astegolimab
Based on 3 publication(s) in Google Scholar
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.00%
- No. CAS: 2173054-79-8
- Peso molecular:144.98 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Astegolimab
More
Customer Validation & Images
-
ELISA
-
WB
Actividad biológica
Human IgG2 kappa
Human
|
ST2 |
Astegolimab could block the effect of CM-induced neutrophil extracellular trap (NET) formation in HL-60 cells[2].
Astegolimab (10 μM) blocks the effect of exogenous IL33 on cardiomyocyte (AC16) senescence[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AC16 cells treated with IL33
-
Concentration:10 μM
-
Incubation Time:
-
Result:Reduced p53 expression.
Mitigated IL33-upregulated SASP factors such as IL1α, IL6 and MCP1.
Mitigated IL33-increased p-p65/p65 ratio.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized ST2/IL1RL1 Protein, Human can bind Astegolimab. The EC50 for this effect is 28.29 ng/mL. -
Loaded ST2/IL1RL1 Protein, Human (310a.a, HEK293, His, HY-P70615) on AHC2 biosensor, can bind Astegolimab with an affinity constant of 2.022E-10 M as determined in BLI assay.
Chemical Information
-
No. CAS 2173054-79-8
-
Appearance Liquid
-
Peso molecular 144.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Astegolimab]
-
Synonyms
MSTT 1041A; RG 6149
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. [Abstract]2026 Jun 8;44(6):1179-1200.e14. PMID: 41997138 -
Cell Oncol (Dordr)
Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. [Abstract]2025 Apr;48(2):487-504. PMID: 39585643
Astegolimab purchased from MedChemExpress. Usage Cited in: Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Abstract]
Astegolimab (IL33-IN). ELISA was used to detect the concentrations of mouse bone marrow-derived ribonuclease (BMDN) and elastase in HL-60 cell supernatant.
Astegolimab purchased from MedChemExpress. Usage Cited in: Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Abstract]
Astegolimab (IL33-IN). Western blot analysis of molecules associated with NET formation in mouse bone marrow-derived macrophages (BMDN).
-
Pureza y Documentación
-
Ficha de datos (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Steven G Kelsen, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-798. [Content Brief]
[2]. Yi N, et al. Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Content Brief]
[3]. Wu L, et al. Mechanistic role of RND3-regulated IL33/ST2 signaling on cardiomyocyte senescence. Life Sci. 2024 Jul 1;348:122701. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz